AR122723A1 - Compuestos de unión de cereblon, composiciones de los mismos, y métodos de tratamiento con los mismos - Google Patents
Compuestos de unión de cereblon, composiciones de los mismos, y métodos de tratamiento con los mismosInfo
- Publication number
- AR122723A1 AR122723A1 ARP210101735A ARP210101735A AR122723A1 AR 122723 A1 AR122723 A1 AR 122723A1 AR P210101735 A ARP210101735 A AR P210101735A AR P210101735 A ARP210101735 A AR P210101735A AR 122723 A1 AR122723 A1 AR 122723A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- unsubstituted
- substituted
- halogen
- cycloalkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 101000941994 Homo sapiens Protein cereblon Proteins 0.000 title 1
- 102100032783 Protein cereblon Human genes 0.000 title 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 3
- 229910052799 carbon Inorganic materials 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 150000001721 carbon Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 102000001307 androgen receptors Human genes 0.000 abstract 1
- 108010080146 androgen receptors Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- -1 piperidine dione compound Chemical class 0.000 abstract 1
- 150000005458 piperidinediones Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Cephalosporin Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063043555P | 2020-06-24 | 2020-06-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR122723A1 true AR122723A1 (es) | 2022-09-28 |
Family
ID=79032408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210101735A AR122723A1 (es) | 2020-06-24 | 2021-06-23 | Compuestos de unión de cereblon, composiciones de los mismos, y métodos de tratamiento con los mismos |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11634407B2 (https=) |
| EP (1) | EP4171566A4 (https=) |
| JP (2) | JP7781792B2 (https=) |
| KR (1) | KR20230027066A (https=) |
| CN (2) | CN120441548A (https=) |
| AR (1) | AR122723A1 (https=) |
| AU (1) | AU2021296833A1 (https=) |
| BR (1) | BR112022025933A2 (https=) |
| CA (1) | CA3182325A1 (https=) |
| CL (1) | CL2022003719A1 (https=) |
| CO (1) | CO2022018653A2 (https=) |
| IL (1) | IL299256A (https=) |
| MX (1) | MX2022015757A (https=) |
| PE (1) | PE20231746A1 (https=) |
| SA (1) | SA522441857B1 (https=) |
| TW (1) | TW202216680A (https=) |
| WO (1) | WO2021262810A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020405129A1 (en) | 2019-12-19 | 2022-06-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| CR20220630A (es) | 2020-05-09 | 2023-01-23 | Arvinas Operations Inc | Métodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificación que comprenden el mismo |
| JP7778095B2 (ja) | 2020-06-24 | 2025-12-01 | セルジーン コーポレーション | セレブロン結合化合物、その組成物及びそれによる治療方法 |
| KR20230027214A (ko) | 2020-06-24 | 2023-02-27 | 셀진 코포레이션 | 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 |
| KR20230027066A (ko) | 2020-06-24 | 2023-02-27 | 셀진 코포레이션 | 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 |
| CN117561249A (zh) * | 2021-06-25 | 2024-02-13 | 细胞基因公司 | Cereblon结合化合物、其组合物及其用于治疗的方法 |
| EP4584259A1 (en) | 2022-09-09 | 2025-07-16 | Innovo Therapeutics, Inc. | Ck1alpha and dual ck1alpha / gspt1 degrading compounds |
| WO2025063888A1 (en) | 2023-09-19 | 2025-03-27 | Kancure Pte. Ltd. | Survivin-targeted compounds |
| TW202535392A (zh) | 2023-12-08 | 2025-09-16 | 美商亞文納營運公司 | 使用雄性素受體降解劑治療脊髓延髓性肌肉萎縮 |
| WO2025179161A1 (en) | 2024-02-21 | 2025-08-28 | Innovo Therapeutics, Inc. | Protein degrading compounds |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101032483B (zh) * | 2006-03-09 | 2011-05-04 | 陈德桂 | 调节雄激素受体活性的乙内酰脲衍生物及其应用 |
| JP6817962B2 (ja) * | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| CN109641874A (zh) * | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| CN110023297A (zh) * | 2016-07-08 | 2019-07-16 | 詹森药业有限公司 | 作为雄性激素受体拮抗剂的取代的乙内酰脲和硫代己内酰脲衍生物 |
| CN110769822A (zh) * | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| WO2020051260A1 (en) * | 2018-09-05 | 2020-03-12 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (sard) ligands and methods of use thereof |
| CN113473987B (zh) | 2018-12-19 | 2024-09-03 | 细胞基因公司 | 被取代的3-((3-氨基苯基)氨基)哌啶-2,6-二酮化合物、其组合物和使用其的治疗方法 |
| CN113453681B (zh) | 2018-12-19 | 2024-10-11 | 细胞基因公司 | 经取代的3-((3-氨基苯基)氨基)哌啶-2，6-二酮化合物、其组合物及使用它们的治疗方法 |
| JP7778095B2 (ja) | 2020-06-24 | 2025-12-01 | セルジーン コーポレーション | セレブロン結合化合物、その組成物及びそれによる治療方法 |
| KR20230027214A (ko) | 2020-06-24 | 2023-02-27 | 셀진 코포레이션 | 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 |
| KR20230027066A (ko) | 2020-06-24 | 2023-02-27 | 셀진 코포레이션 | 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 |
-
2021
- 2021-06-23 KR KR1020227044904A patent/KR20230027066A/ko active Pending
- 2021-06-23 PE PE2022003029A patent/PE20231746A1/es unknown
- 2021-06-23 CN CN202510574007.2A patent/CN120441548A/zh active Pending
- 2021-06-23 WO PCT/US2021/038618 patent/WO2021262810A1/en not_active Ceased
- 2021-06-23 CA CA3182325A patent/CA3182325A1/en active Pending
- 2021-06-23 TW TW110122923A patent/TW202216680A/zh unknown
- 2021-06-23 AU AU2021296833A patent/AU2021296833A1/en active Pending
- 2021-06-23 EP EP21827824.0A patent/EP4171566A4/en active Pending
- 2021-06-23 US US17/356,370 patent/US11634407B2/en active Active
- 2021-06-23 AR ARP210101735A patent/AR122723A1/es unknown
- 2021-06-23 JP JP2022580090A patent/JP7781792B2/ja active Active
- 2021-06-23 BR BR112022025933A patent/BR112022025933A2/pt unknown
- 2021-06-23 CN CN202180044295.0A patent/CN115835866B/zh active Active
- 2021-06-23 MX MX2022015757A patent/MX2022015757A/es unknown
- 2021-06-23 IL IL299256A patent/IL299256A/en unknown
-
2022
- 2022-12-22 CO CONC2022/0018653A patent/CO2022018653A2/es unknown
- 2022-12-22 CL CL2022003719A patent/CL2022003719A1/es unknown
- 2022-12-22 SA SA522441857A patent/SA522441857B1/ar unknown
-
2023
- 2023-03-16 US US18/122,496 patent/US12103920B2/en active Active
-
2024
- 2024-07-18 US US18/776,606 patent/US20250188056A1/en active Pending
-
2025
- 2025-11-26 JP JP2025203650A patent/JP2026035702A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250188056A1 (en) | 2025-06-12 |
| CA3182325A1 (en) | 2021-12-30 |
| EP4171566A4 (en) | 2024-07-24 |
| SA522441857B1 (ar) | 2024-07-21 |
| PE20231746A1 (es) | 2023-11-06 |
| US20210403454A1 (en) | 2021-12-30 |
| US20230242509A1 (en) | 2023-08-03 |
| IL299256A (en) | 2023-02-01 |
| US11634407B2 (en) | 2023-04-25 |
| JP7781792B2 (ja) | 2025-12-08 |
| JP2026035702A (ja) | 2026-03-04 |
| WO2021262810A1 (en) | 2021-12-30 |
| CN115835866B (zh) | 2025-05-02 |
| KR20230027066A (ko) | 2023-02-27 |
| AU2021296833A1 (en) | 2023-01-19 |
| CL2022003719A1 (es) | 2023-05-12 |
| CN120441548A (zh) | 2025-08-08 |
| JP2023533203A (ja) | 2023-08-02 |
| MX2022015757A (es) | 2023-01-19 |
| US12103920B2 (en) | 2024-10-01 |
| EP4171566A1 (en) | 2023-05-03 |
| CN115835866A (zh) | 2023-03-21 |
| TW202216680A (zh) | 2022-05-01 |
| CO2022018653A2 (es) | 2023-03-27 |
| BR112022025933A2 (pt) | 2023-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR122723A1 (es) | Compuestos de unión de cereblon, composiciones de los mismos, y métodos de tratamiento con los mismos | |
| AR122725A1 (es) | Compuestos de unión de cereblon, composiciones de los mismos, y métodos de tratamiento con los mismos | |
| AR122726A1 (es) | Compuestos de unión de cereblon, composiciones de los mismos, y métodos de tratamiento con los mismos | |
| PE20221336A1 (es) | Compuestos triciclicos sustituidos | |
| AR089865A1 (es) | Derivados de bencimidazol e imidazopiridinas como moduladores de canales de sodio | |
| AR089019A1 (es) | Derivados modificados de 4-fenil-piridina | |
| AR115296A1 (es) | Heterocíclicos inhibidores de mat2a y métodos de uso para el tratamiento del cáncer | |
| AR113299A1 (es) | Compuestos de isoindolina | |
| AR121078A1 (es) | Derivados de arilamida con actividad antitumoral | |
| AR107714A1 (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| PE20190912A1 (es) | Compuesto de piridona como inhibidor de c-met | |
| AR086546A1 (es) | Derivados de 7h-purin-8(9h)-ona como inhibidores de jak | |
| AR116114A1 (es) | Amidas heterocíclicas de entre 5 y 7 miembros como inhibidores de jak | |
| AR119728A1 (es) | Derivados de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4]tiadiazina como inhibidores de mrgx2 | |
| AR112831A1 (es) | Terapia de combinación usando un antagonista del receptor 2 de quimiocina (ccr2) y un inhibidor de pd-1 / pd-l1 | |
| AR092288A1 (es) | Ligandos del receptor ep1 | |
| CL2011002859A1 (es) | Compuestos espironucleosidos, inhibidores del virus vhc; composicion farmaceutica de dichos compuestos; uso del compuesto para tratar la hepatitis c. | |
| AR117206A1 (es) | Derivados de octahidropirrolo[2,1-b][1,3]tiazepin-7-carboxamido útiles en la terapia para el vih y para el tratamiento del cáncer | |
| AR118521A1 (es) | Compuestos y composiciones farmacéuticas de los mismos para el tratamiento de trastornos inflamatorios | |
| AR119376A1 (es) | Compuestos heterocíclicos | |
| AR103629A1 (es) | Compuestos con actividad antitumoral | |
| AR124582A1 (es) | Compuestos de aminotiazol como inhibidores de c-kit | |
| AR057377A1 (es) | Derivados de cicloheptapiridina como inhibidores de tirosina quinasa. composiciones farmaceuticas | |
| AR120170A1 (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 | |
| AR124749A1 (es) | Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de enfermedades |